<DOC>
	<DOCNO>NCT01156584</DOCNO>
	<brief_summary>This multicenter , open-label , ascending-dose trial safety tolerability increase dos Toca 511 , Retroviral Replicating Vector ( RRV ) , administer subject recurrent high grade glioma ( rHGG ) undergone surgery follow adjuvant radiation therapy chemotherapy . Subjects recieve Toca 511 via stereotactic , transcranial injection tumor . Cohort 7 &amp; 9 receive Toca 511 intravenous injection give daily 3 &amp; 5 day respectively . Approximately 3-4 week follow injection RRV , treatment Toca FC commence repeat approximately every 6 week study completion enrollment continuation study .</brief_summary>
	<brief_title>A Study Retroviral Replicating Vector Administered Subjects With Recurrent Malignant Glioma</brief_title>
	<detailed_description>There ongoing , intensive search novel therapy improve prognosis patient common aggressive form primary brain cancer , glioblastoma multiforme ( GBM ) . Gene transfer one approach . Early gene-transfer study replication incompetent vector show approach generally safe , ineffective due limit transduction tumor . More recently gene transfer attempt oncolytic , replicate virus . However viruses rapidly clear immune system . To overcome shortcoming previous gene transfer protocol , Toca 511 develop utilize Retroviral Replicating Vector ( RRV ) . This platform follow potential advantage : 1 ) The vector infect divide cell , 2 ) The virus stably integrate genome tumor cell allow potential long-term control tumor , 3 ) The virus intrinsically oncolytic clear tumor immune system , 4 ) The virus engineer express prodrug-activator , cytosine deaminase ( CD ) , gene catalyzes intracellular conversion antifungal drug , 5-FC ( flucytosine ) cytotoxic drug 5-FU . In xenograft syngeneic intracranial mouse tumor model Toca 511/5-FC combination able significantly increase survival treated animal . The goal current trial demonstrate safety efficacy Toca 511 administer intratumorally patient recurrent GBM follow cyclic treatment prodrug 5-FC .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>least 18 year age intratumoral cohort , supratentorial HGG ( WHO grade III IV ) technically unresectable HGG initial definitive therapy surgery without adjuvant radiation subject elect undergo treatment Gliadel wafer receive corticosteroid , dose stable decrease past 7 day KPS : least 70 absolute neutrophil count &gt; 1500/mm^3 absolute lymphocyte count &gt; 500/mm^3 platelet count &gt; 100,000/mm^3 hemoglobin &gt; 10 g/dL intratumoral cohort , coagulation profile favorable surgery estimate glomerular filtration rate &gt; 50 mL/min ALT &lt; 3 time ULN bilirubin &lt; 1.5 mg/dL negative serum pregnancy test cytotoxic therapy within past 4 week ( 6 week BCNU/CCNU ) 2 recurrence include present recurrence Gliadel wafer wafer implant within past 8 week take 8 mg dexamethasone per day intratumoral cohort , injection tumor would require violation ventricular system infection require antibiotic , anticoagulant , antiplatelet agent within past 4 week intratumoral cohort , bleed diathesis use anticoagulants/antiplatelet agent stop allergy intolerance 5FC HIV positive g.i . condition would prevent ingestion absorption 5FC investigational treatment within past 30 day pregnant breast feeding receive Avastin history prior malignancy , exclude basal squamous cell carcinoma skin , expect survival le 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>glioma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>Grade IV astrocytoma</keyword>
	<keyword>brain cancer</keyword>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>AA</keyword>
	<keyword>AOD</keyword>
	<keyword>anaplastic astrocytoma</keyword>
	<keyword>anaplastic oligodendroglioma</keyword>
	<keyword>anaplastic oligoastrocytoma</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>high grade glioma</keyword>
</DOC>